Precisely targeting the interface between
innate and adaptive immunity.
 

SV Life Sciences is a venture capital adviser and manager that makes selected investments in businesses with experienced entrepreneurs and management teams. SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences' currently advises or manages five funds with capital commitments of approximately $1.6 billion that primarily invest amounts of between $1m and $20m in North America and Europe, but will consider innovative investments in other regions. SV Life Sciences team of 34 professionals has a diverse, complimentary set of skills and experience that allow SV Life Sciences to tailor a team to work with almost any life sciences business.  SVLS was established in 1993 and currently has offices in Boston, San Francisco and London.  For more information, please visit the company's website at http://www.svlsa.com.


MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies.  It was created in 2002 to leverage MedImmune's expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies.  MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics.  MedImmune Ventures primarily seeks to invest in areas of strategic interest to Astra Zeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease.  For more information, please visit http://www.medimmune.com/ventures/overview.asp.